GlassScriptPhysician profile
Paul B Mckee
NPI 1770609125
$1,629.74
in general payments reported to CMS, 2019-2025
22 companies · $129 in 2025
The $129 reported for 2025 was more than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
See the full distribution for Sports Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $315 · 2021: $274 · 2022: $215 · 2023: $136 · 2024: $102 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $367.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $800.25 | 2019-2022 | |
| Pacira Therapeutics, INC. | $217.09 | 2019-2020 | |
| Alpha Orthopedic Systems | $89.80 | 2020-2023 | |
| Medtronic, INC. | $65.47 | 2024-2025 | Synchromedii, Aquamantys(Tm) |
| Ferring Pharmaceuticals INC. | $57.45 | 2019-2025 | Euflexxa |
| Depuy Synthes Sales INC. | $49.91 | 2019-2025 | Orthovisc, Monovisc |
| Pfizer INC. | $49.01 | 2020-2021 | |
| Stryker Corporation | $42.63 | 2023 | Biosteon |
| Blue Surgical LLC | $30.86 | 2024 | |
| Sanofi-Aventis U.S. LLC | $30.35 | 2019 | |
| Polynovo North America LLC | $21.37 | 2025 | Novosorb Btm |
| Melinta Therapeutics, LLC | $21.20 | 2023 | Orbactiv, Kimyrsa |
| Zimmer Biomet Holdings, INC. | $20.65 | 2023 | Gel-One Cross-Linked Hyaluronate |
| Smith+Nephew, INC. | $20.25 | 2022 | |
| Amgen INC. | $17.87 | 2024 | Evenity, Prolia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $17.48 | 2022 | |
| Bioventus LLC | $15.00 | 2025 | Durolane |
| Kerecis Limited | $14.36 | 2022 | |
| Boston Scientific Corporation | $14.33 | 2019 | |
| Vericel Corporation | $14.32 | 2023 | Maci |
| Flowonix Medical Incorporated | $11.61 | 2019 | |
| Next Science LLC | $8.48 | 2023 | Xperience, Blastx, Surgx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Mckee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.